SCHEMBL23928110

SCHEMBL23928110

COCCN(CCOC)c1ccc(CCNC(=O)O)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ESRRG P62508 5/20 0.52
ESRRB O95718 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.43
CNR1 P21554 2/20 0.43
FPR2 P25090 1/20 0.43
GLA P06280 1/20 0.43
KMT2A Q03164 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
ALDH1A1 P00352 3/20 0.42
TAAR1 Q96RJ0 2/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23291135 0.93 ESRRG (0.56) ESRRGESRRBSMN1; SMN2CNR1FPR2
SCHEMBL23928220 0.87 ALDH1A1 (0.42) ESRRGESRRBSMN1; SMN2CNR1GLA
SCHEMBL23291150 0.83 NAMPT (0.49) ESRRGESRRBCNR1GLAKMT2A
SCHEMBL16059019 0.79 CALM1 (0.42) ESRRGSMN1; SMN2KMT2AALDH1A1LMNA
SCHEMBL23291328 0.77 ESRRG (0.51) ESRRGESRRBCNR1GLAKMT2A
SCHEMBL23291226 0.77 MAPT (0.48) SMN1; SMN2CNR1FPR2GLAKMT2A
SCHEMBL23928140 0.77 KMT2A (0.59) SMN1; SMN2GLAKMT2AALDH1A1TAAR1
SCHEMBL18562084 0.74 KMT2A (0.37) KMT2AALDH1A1LMNARAB9AMAPT
SCHEMBL23928227 0.73 TAAR1 (0.48) KMT2AALDH1A1TAAR1KDM4E
SCHEMBL4583404 0.73 SMN1; SMN2 (0.75) SMN1; SMN2FPR2GLAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 CN disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
CN-111051309-A Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2020-04-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 ESRRG 1064/4885ESRRB 1201/4885SMN1; SMN2 4178/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 ESRRG 1064/4885ESRRB 1201/4885SMN1; SMN2 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.